EFFICACY AND SAFETY OF LUVELTAMAB TAZEVIBULIN IN PATIENTS WITH RECURRENT PLATINUM-RESISTANT OVARIAN CANCER: THE REFRAME-01 (GOG-3086, ENGOT-79OV, AND APGOT-OV9) PHASE 2/3 STUDY (IGCS 2024) - Oct 4, 2024 - Abstract #TP010 / #1537; P2/3 | " Randomized, open-label, phase 2/3 study evaluating the efficacy and safety of luvelta vs investigator's choice chemotherapy (ICC; gemcitabine, paclitaxel, pegylated liposomal doxorubicin, or topotecan) in patients with recurrent PROC expressing FRα (NCT05870748). Current Trial Status: Part 1 is closed and part 2 has recently opened enrolment, planning to recruit approx. 550 patients."
Clinical • P2/3 data • Oncology • Ovarian Cancer • Solid Tumor • FOLR1 • PROC
|
|
Ana Oaknin 1; Domenica Lorusso 2; Klaus Pietzner 3; Jung-Yun Lee 4; David Cibula 5; Yeh Chen Lee 6; Russell Schilder 7; Annika Auranen 8; Bo Gao 9; David Tan 10; Amit Oza 11; Rowan Miller 12; Vanda Salutari 13; Giulia Tasca 14; David O'Malley 15; Bradley Monk 16; Bhavana Pothuri 17; Lin Lu 18; Craig Berman 18; Anne Borgman 18; R. Wendel Naumann 19
|